Gilder Gagnon Howe & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-243,836	Closed	-$20.2M	–	280
2016 Q4	$20.2M	Sell	243,836 -199,870	-45%	-$17.2M	0.4%	68
2016 Q3	$41.1M	Sell	443,706 -17,983	-4%	-$1.69M	0.71%	47
2016 Q2	$35.9M	Sell	461,689 -9,487	-2%	-$807K	0.71%	47
2016 Q1	$38.9M	Sell	471,176 -9,220	-2%	-$750K	0.76%	33
2015 Q4	$50.3M	Sell	480,396 -4,766	-1%	-$498K	0.81%	31
2015 Q3	$51.1M	Sell	485,162 -141,338	-23%	-$18.9M	0.81%	34
2015 Q2	$85.7M	Sell	626,500 -289,936	-32%	-$35.9M	1.13%	25
2015 Q1	$114M	Sell	916,436 -146,826	-14%	-$15.6M	1.59%	16
2014 Q4	$96.1M	Sell	1,063,262 -25,748	-2%	-$2.14M	1.43%	22
2014 Q3	$78.6M	Sell	1,089,010 -12,714	-1%	-$836K	1.14%	22
2014 Q2	$68.5M	Sell	1,101,724 -3,886	-0.4%	-$235K	0.91%	28
2014 Q1	$75.4M	Sell	1,105,610 -23,125	-2%	-$1.7M	1.03%	28
2013 Q4	$79.4M	Sell	1,128,735 -132,637	-11%	-$9.01M	1.13%	27
2013 Q3	$91M	Sell	1,261,372 -26,240	-2%	-$1.74M	1.42%	19
2013 Q2	$71.8M	Buy	+1,287,612	New	+$80.2M	1.35%	21

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Gilder Gagnon Howe & Co's BMRN Position: Q1 2017 in Review

Gilder Gagnon Howe & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 243,836 shares — an estimated $20.2M sold.

Gilder Gagnon Howe & Co first reported a position in BMRN in Q2 2013 and held it in 15 quarters. The position peaked at $114M in Q1 2015. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Gilder Gagnon Howe & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 243,836 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $20.2M.
Gilder Gagnon Howe & Co first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Gilder Gagnon Howe & Co's BioMarin Pharmaceuticals position peaked at $114M in Q1 2015.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2017, filed 11 May 2017.